Rep. Thomas H. Kean, Jr. Buys Illumina, Inc. (NASDAQ:ILMN) Shares

Representative Thomas H. Kean, Jr. (R-New Jersey) recently bought shares of Illumina, Inc. NASDAQ: ILMN. In a filing disclosed on April 18th, the Representative disclosed that they had bought between $1,001 and $15,000 in Illumina stock on April 1st. The trade occurred in the Representative's "KEAN FAMILY PARTNERSHIP" account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of nVent Electric NYSE: NVT on 4/1/2025.
• Purchased $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 2/26/2025.
• Sold $15,001 - $50,000 in shares of Stryker NYSE: SYK on 2/26/2025.
• Sold $1,001 - $15,000 in shares of Magnera NYSE: MAGN on 2/12/2025.
• Sold $1,001 - $15,000 in shares of Pernod Ricard OTC: PRNDY on 2/7/2025.
• Purchased $1,001 - $15,000 in shares of Mondelez International NASDAQ: MDLZ on 2/7/2025.
• Purchased $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 1/31/2025.

Illumina Price Performance

Shares of NASDAQ:ILMN traded up $1.90 during trading on Wednesday, reaching $76.25. The stock had a trading volume of 1,661,007 shares, compared to its average volume of 2,276,444. The stock has a market capitalization of $12.07 billion, a PE ratio of -9.93, a P/E/G ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The business's 50-day moving average price is $82.95 and its 200 day moving average price is $119.06. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Hedge Funds Weigh In On Illumina

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bleakley Financial Group LLC bought a new position in Illumina in the 4th quarter valued at about $751,000. Van ECK Associates Corp lifted its holdings in Illumina by 17.5% during the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company's stock worth $20,347,000 after purchasing an additional 22,718 shares during the last quarter. Allworth Financial LP boosted its stake in Illumina by 720.7% in the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company's stock valued at $1,001,000 after purchasing an additional 6,263 shares during the period. Strategic Financial Concepts LLC acquired a new position in Illumina in the 4th quarter valued at $1,464,000. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Illumina during the 4th quarter worth $448,000. 89.42% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ILMN shares. Hsbc Global Res cut Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. TD Cowen cut shares of Illumina from a "buy" rating to a "hold" rating and reduced their price target for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Citigroup lowered their price objective on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. HSBC lowered Illumina from a "buy" rating to a "hold" rating and set a $100.00 target price on the stock. in a report on Friday, February 28th. Finally, Royal Bank of Canada dropped their price target on Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $138.70.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election. Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.